Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

which was related to a one-time voluntary retirement scheme (VRS). Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic ...

A pooled analysis of both trials showed notable reductions from baseline in nasal polyp score (NPS) at 52 weeks and mean nasal obstruction scores (VRS) for over weeks 49-52. GSK said that ...